FrancophonIA/ELRC3.0 huggingface dataset:
English: The following adverse reactions were observed in a pooled analysis of the HEC and MEC studies at a greater incidence with aprepitant than with standard therapy in adults or postmarketing use:
Croatian: Sljedeće nuspojave zabilježene su u zbirnoj analizi podataka iz HEC i MEC ispitivanja s većom incidencijom uz aprepitant nego uz standardnu terapiju u odraslih ili u razdoblju nakon stavljanja lijeka u promet:
English: Titanium dioxide (E 171) Red iron oxide (E 172) Yellow iron oxide (E 172)
Croatian: Ovojnica kapsule (125 mg) želatina titanijev dioksid (E 171) željezov oksid, crveni (E 172) željezov oksid, žuti (E 172)
English: Figure 1 Percent of adult patients receiving Highly Emetogenic Chemotherapy who remain emesis free over time - Cycle 1
Croatian: Slika 1 Postotak odraslih bolesnika koji su primali jako emetogenu kemoterapiju i koji određeno vrijeme nisu povraćali - 1. ciklus
English: Efficacy was based on evaluation of the following composite measure: complete response (defined as no emetic episodes and no use of rescue therapy) primarily during Cycle 1.
Croatian: Djelotvornost je ocijenjena na temelju sljedeće kompozitne mjere učinka: potpuni odgovor (definiran kao izostanak povraćanja i bez primjene dodatnih lijekova za olakšanje simptoma), prvenstveno u prvom ciklusu liječenja.
English: Each 125 mg hard capsule contains 125 mg of aprepitant.
Croatian: Jedna tvrda kapsula od 125 mg sadrži 125 mg aprepitanta.
English: 6 Aluminium blisters each containing one 165 mg capsule.
Croatian: 6 aluminijskih blistera sa po jednom kapsulom od 165 mg.
English: Gastrointestinal disorders constipation, dyspepsia common eructation, nausea*, vomiting*, gastroesophageal reflux disease, abdominal pain, dry mouth, flatulence uncommon duodenal ulcer perforation, stomatitis, abdominal distension, faeces hard, neutropenic colitis rare
Croatian: često podrigivanje, mučnina*, povraćanje*, gastroezofagealna refluksna bolest, bol u abdomenu, suha usta, flatulencija manje često perforacija duodenalnog ulkusa, stomatitis, abdominalna distenzija, tvrda stolica, neutropenični kolitis rijetko
English: In pharmacokinetic studies, EMEND, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, did not influence the pharmacokinetics of docetaxel administered intravenously on Day 1 or vinorelbine administered intravenously on Day 1 or Day 8.
Croatian: U ispitivanjima farmakokinetike, primjena lijeka EMEND u dozi od 125 mg 1. dana te 80 mg na dan 2. i 3. dan liječenja nije utjecala na farmakokinetiku docetaksela primijenjenog intravenski 1. dan liječenja, odnosno vinorelbina primijenjenog intravenski 1. ili 8. dan liječenja.
English: Each capsule contains 80 mg of sucrose (in the 80 mg capsule).
Croatian: Pomoćna tvar s poznatim učinkom Jedna kapsula sadrži 80 mg saharoze (u kapsuli od 80 mg).
English: EMEND may be taken with or without food.
Croatian: EMEND se može uzimati s hranom ili bez nje.
English: EMEND 40 mg hard capsules
Croatian: EMEND 40 mg tvrde kapsule
English: Aluminium blister containing one 80 mg capsule.
Croatian: Aluminijski blister s jednom kapsulom od 80 mg.
English: EMEND 125 mg hard capsule EMEND 80 mg hard capsules Aprepitant
Croatian: EMEND 125 mg tvrde kapsule EMEND 80 mg tvrde kapsule aprepitant
English: oC and 8
Croatian: 4.8 Nuspojave
English: EMEND 125 mg powder for oral suspension aprepitant
Croatian: EMEND 125 mg prašak za oralnu suspenziju aprepitant
English: Each 80 mg hard capsule contains 80 mg of aprepitant.
Croatian: Jedna tvrda kapsula od 80 mg sadrži 80 mg aprepitanta.
English: What EMEND looks like and contents of the pack The 165 mg hard capsule is opaque with a light blue cap and a white body with “466” and “165 mg” printed radially in black ink on one side of the body and the Merck logo on the other side.
Croatian: EMEND 165 mg tvrda kapsula je neprozirna, sa svijetloplavom kapicom i bijelim tijelom te poprečno otisnutim crnim oznakama "466" i "165 mg" na jednoj strani tijela kapsule i Merck logom na drugoj strani kapsule.
English: The fosaprepitant regimen consisted of fosaprepitant 150 mg on Day 1 in combination with intravenous ondansetron 32 mg on Day 1 and dexamethasone 12 mg on Day 1, 8 mg on Day 2, and 8 mg twice daily on Days 3 and 4.
Croatian: Režim liječenja fosaprepitantom sastojao se od jedne doze fosaprepitanta od 150 mg 1. dan liječenja, u kombinaciji s ondanzetronom 32 mg primijenjenim intravenski 1. dan liječenja i deksametazonom u dozi od 12 mg 1. dan, 8 mg 2. dan te 8 mg dvaput na dan 3. i 4. dan liječenja.
English: Because the effect of EMEND on the pharmacokinetics of orally administered CYP3A4 substrates is greater than the effect of EMEND on the pharmacokinetics of intravenously administered CYP3A4 substrates, an interaction with orally administered chemotherapeutic medicinal products metabolised primarily or partly by CYP3A4 (e.g.,
Croatian: Budući da EMEND snažnije utječe na farmakokinetiku supstrata CYP3A4 koji se daju peroralno nego onih koji se daju intravenski, ne može se isključiti interakcija s peroralnim kemoterapeuticima koji se primarno ili dijelomično metaboliziraju putem CYP3A4 (npr. etopozidom ili vinorelbinom).
English: EMEND 125 mg hard capsules EMEND 80 mg hard capsules
Croatian: EMEND 125 mg tvrde kapsule EMEND 80 mg tvrde kapsule
English: 125 mg orally 80 mg orally 80 mg orally none
Croatian: 125 mg peroralno 80 mg peroralno
English: EMEND 165 mg hard capsules aprepitant
Croatian: EMEND 165 mg tvrde kapsule aprepitant
English: Efficacy was based on evaluation of the composite measure: complete response (defined as no emetic episodes and no use of rescue therapy) primarily during Cycle 1.
Croatian: Djelotvornost je ocijenjena na temelju sljedeće kompozitne mjere: potpuni odgovor (definiran kao izostanak povraćanja i bez primjene dodatnih lijekova za olakšanje simptoma), prvenstveno u prvom ciklusu liječenja.
English: After reconstitution, 1 mL oral suspension contains 25 mg of aprepitant - The other ingredients are: hydroxypropyl-cellulose (E 463), sodium laurilsulfate (E 487), sucrose and lactose (see section 2 under ‘EMEND contains sucrose and lactose'), red iron oxide (E 172) and sodium stearyl fumarate (E 485).
Croatian: Drugi sastojci su: hidroksipropilceluloza (E463), natrijev laurilsulfat (E487), saharoza i laktoza (pogledajte dio 2 „EMEND sadrži saharozu i laktozu“), crveni željezov oksid (E172) i natrijev stearilfumarat (E485).
English: Aprepitant, when given as a single dose of 200 mg in the fed state (standard light breakfast) on Day 1 with oral dexamethasone, co-administered orally as 12 mg on Day 1 and 8 mg on Days 2 through 4, increased the AUC0-24hr of dexamethasone by 2.1- and 2.3-fold on Days 1 and 2, to a lesser extent (1.4-fold increase) on Day 3, and had no effect on Day 4 (1.1-fold).
Croatian: Istodobna peroralna primjena deksametazona, 1. dan liječenja u dozi od 12 mg, te 8 mg 2 do 4. dana liječenja i jednokratne doze aprepitanta od 200 mg primjenjene 1. dan liječenja na pun želudac (standardni lagani doručak), povećala je AUC0-24hr deksametazona za 2,1 puta i 2,3 puta 1. i 2. dan liječenja, te u manjoj mjeri 3 dan.
English: When a single 125 mg dose of EMEND was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilised on chronic warfarin therapy, there was no effect of EMEND on the plasma AUC of R(+) or S(-) warfarin determined on Day 3; however, there was a 34 % decrease in S(-) warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14 % decrease in INR 5 days after completion of treatment with EMEND.
Croatian: Prilikom primjene jedne doze lijeka EMEND 125 mg 1. dan te 80 mg na dan 2. i 3. dan liječenja zdravim ispitanicima čije je stanje stabilizirano kroničnim liječenjem varfarinom, 3. dan liječenja nije opažen nikakav učinak lijeka EMEND na AUC R(+), odnosno S(-) varfarina u plazmi; međutim, 5 dana nakon završetka liječenja lijekom EMEND zamijećeno je sniženje najniže koncentracije S(-) varfarina (supstrata CYP2C9) od 34%, praćeno sniženjem INR-a od 14%.
English: Each capsule contains 125 mg of sucrose (in the 125 mg capsule).
Croatian: Pomoćna tvar s poznatim učinkom Jedna kapsula sadrži 125 mg saharoze (u kapsuli od 125 mg).
English: The aprepitant regimen consisted of aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 and 3 in combination with intravenous ondansetron 32 mg on Day 1 and dexamethasone 12 mg on Day 1 and 8 mg daily on Days 2 through 4.
Croatian: Režim liječenja aprepitantom sastojao se od 125 mg aprepitanta 1. dan te 80 mg/dan 2. i 3. dan liječenja, u kombinaciji s ondanzetronom 32 mg primijenjenim intravenski 1. dan liječenja i deksametazonom u dozi od 12 mg 1. dana te 8 mg 2. do 4. dana liječenja.
English: Another or additional non-hormonal form of birth control should be used during treatment with EMEND and for up to 2 months after using EMEND, - pimozide (used to treat psychiatric illnesses), - terfenadine; astemizole (used for hay fever and other allergic conditions), - cisapride (used for treating digestive problems), - medicines containing ergot alkaloid derivatives (used for treating migraines), - rifampicin, clarithromycin, telithromycin (antibiotics used to treat infections), - phenytoin (a medicine used to treat seizures), - carbamazepine (used to treat depression and epilepsy), - midazolam, phenobarbital (medicines used to produce calmness or help you sleep), - St. John's Wort (an herbal preparation used to treat depression), - protease inhibitors (used to treat HIV infections), - nefazodone (used to treat depression), - ketoconazole except shampoo (used to treat Cushing's syndrome - when the body produces an excess of cortisol), - itraconazole, voriconazole, posaconazole (antifungals), - corticosteroids (such as dexamethasone)
Croatian: Treba koristiti zamjenske ili dodatne nehormonske metode kontracepcije za vrijeme i do 2 mjeseca nakon primjene lijeka EMEND, - pimozid (za liječenje psihičkih bolesti), - terfenadin; astemizol (za liječenje peludnih i drugih alergija), - cisaprid (za liječenje probavnih problema), - lijekove koji sadrže derivate ergot alkaloida (za liječenje migrene), - rifampicin, klaritromicin, telitromicin (antibiotici za liječenje infekcija), - fenitoin (lijek za liječenje epileptičkih napadaja), - karbamazepin (za liječenje depresije i epilepsije), - midazolam, fenobarbital (lijekovi za smirenje ili spavanje), - gospinu travu (biljni lijek za liječenje depresije), - inhibitore proteaze (za liječenje HIV infekcije), - nefazodon (za liječenje depresije), - ketokonazol, izuzev šampona (primjenjuje se za liječenje Cushingovog sindroma - kad se u tijelu stvara previše kortizola) - itrakonazol, vorikonazol, posakonazol (za liječenje gljivičnih infekcija) - kortikosteroide (poput deksametazona).
English: These effects were not considered clinically important.
Croatian: Ovi se učinci nisu smatrali kliničkivažnima.
English: Table 4 Percent of adult patients receiving Highly Emetogenic Chemotherapy responding by treatment group and phase - Cycle 1
Croatian: Tablica 4 Postotak odraslih bolesnika koji su primali jako emetogenu kemoterapiju i koji su reagirali na liječenje, prema terapijskoj skupini i fazi liječenja - 1. ciklus
English: Uncommon side effects (may affect up to 1 in 100 people) are: - upper stomach pain, bowel sounds abnormal, dry mouth, nausea, stomach discomfort, serious constipation, small bowel not working properly (sub-ileus), - decreased feeling or sensitivity (especially in skin), sensory disturbance, difficulty in speaking, - decrease in pupil size, decrease in sharpness of vision (vision loss), - inability to sleep, - slow heartbeat, - whistling sound while breathing, shortness of breath.
Croatian: ozbiljni zatvor, nepravilan rad tankog crijeva (sub-ileus), - oslabljena osjetljivost (osobito u koži), poremećaji osjeta, poteškoće s govorom, - smanjena veličina zjenice, smanjena oštrina vida (gubitak vida), - nemogućnost spavanja, - usporeni otkucaji srca, - zviždanje u plućima pri disanju, nedostatak zraka.
English: The 80 mg hard capsule is opaque with a white cap and body with “461” and “80 mg” printed radially in black ink on the body.
Croatian: EMEND 80 mg tvrda kapsula je neprozirna, s bijelim tijelom i bijelom kapicom te poprečno otisnutim crnim oznakama "461" i "80 mg" na tijelu kapsule.
English: It may harm them, even if their signs of illness are the same.
Croatian: Može im naškoditi, čak i ako su njihovi znakovi bolesti jednaki.
English: EMEND 125 mg hard capsules Aprepitant
Croatian: EMEND 125 mg tvrde kapsule aprepitant
English: Gastrointestinal disorders constipation, dyspepsia common eructation, nausea
Croatian: Poremećaji probavnog sustava konstipacija, dispepsija često podrigivanje, mučnina
English: EU/1/03/262/009 1 hard capsule EU/1/03/262/010 6 x 1 hard capsule
Croatian: EU/1/03/262/009 1 tvrda kapsula EU/1/03/262/010 6 x 1 tvrda kapsula
English: Capsules are opaque with a white body and mustard yellow cap with “464” and “40 mg” printed radially in black ink on the body.
Croatian: Kapsule su neprozirne, s bijelim tijelom i žućkastom kapicom te poprečno otisnutim crnim oznakama "464" i "40 mg" na tijelu kapsule.
English: The 80 mg capsules are opaque with a white body and cap with “461” and “80 mg” printed radially in black ink on the body.
Croatian: Kapsule od 80 mg su neprozirne, s bijelim tijelom i bijelom kapicom te poprečno otisnutim crnim oznakama "461" i "80 mg" na tijelu kapsule.
English: Check the EMEND mixture for any clumps or foaming: - If any clumps are present, repeat Step 7 until there are no clumps.
Croatian: Ako primijetite grudice, ponovite korak br.7 sve dok ih više ne bude.
English: EU/1/03/262/001 1 hard capsule EU/1/03/262/002 2 x 1 hard capsule EU/1/03/262/003 5 x 1 hard capsule
Croatian: EU/1/03/262/001 1 tvrda kapsula EU/1/03/262/002 2 x 1 tvrda kapsula EU/1/03/262/003 5 x 1 tvrda kapsula
English: Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious reactions.
Croatian: Inhibicija CYP3A4 aprepitantom može povisiti koncentracije tih djelatnih tvari u plazmi, što može prouzročiti ozbiljne reakcije.
English: These fertility studies did not indicate direct or indirect harmful effects with respect to mating performance, fertility, embryonic/foetal development, or sperm count and motility (see section 5.3).
Croatian: Ta ispitivanja plodnosti nisu ukazala na izravne ili neizravne štetne učinke na parenje, plodnost, embriofetalni razvoj te broj i pokretljivost spermija (vidjeti dio 5.3).
English: Table 1 Percent of adult patients receiving Highly Emetogenic Chemotherapy responding by treatment group and phase - Cycle 1
Croatian: Tablica 1 Postotak odraslih bolesnika koji su primali jako emetogenu kemoterapiju i koji su odgovorili na liječenje, prema terapijskoj skupini i fazi liječenja - 1. ciklus
English: Each hard capsule contains 80 mg of aprepitant.
Croatian: Jedna tvrda kapsula sadrži 80 mg aprepitanta.
English: Additional adverse reactions were observed in adult patients treated with aprepitant for postoperative nausea and vomiting (PONV) and a greater incidence than with ondansetron: abdominal pain upper, bowel sounds abnormal, constipation*, dysarthria, dyspnoea, hypoaesthesia, insomnia, miosis, nausea, sensory disturbance, stomach discomfort, sub-ileus*, visual acuity reduced, wheezing.
Croatian: Dodatne nuspojave zabilježene su u većoj incidenciji u odraslih bolesnika koji su primali aprepitant zbog sprječavanja postoperativne mučnine i povraćanja (engl. postoperative nausea and vomiting, PONV) nego u bolesnika koji su primali ondanzetron: bol u gornjem dijelu abdomena, neobični zvukovi u crijevima, konstipacija*, dizartrija, dispneja, hipoestezija, nesanica, mioza, mučnina, poremećaj osjeta, nelagoda u trbuhu, subileus*, smanjena oštrina vida, piskanje pri disanju.
English: Co-administration with warfarin (a CYP2C9 substrate)
Croatian: Istodobna primjena s varfarinom (supstratom CYP2C9) U bolesnika na kroničnom liječenju varfarinom protrombinsko vrijeme (engl.
English: In patients on chronic warfarin therapy, the International Normalised Ratio (INR) should be monitored closely during treatment with EMEND and for 14 days following the use of EMEND (see section 4.5).
Croatian: International Normalised Ratio, INR) treba strogo nadzirati za vrijeme liječenja lijekom EMEND i tijekom 14 dana nakon svake primjene lijeka EMEND (vidjeti dio 4.5).
English: Another or additional non-hormonal form of birth control should be used during treatment with EMEND and for up to 2 months after using EMEND, - cyclosporine, tacrolimus, sirolimus, everolimus (immunosuppressants), - alfentanil, fentanyl (used to treat pain), - quinidine (used to treat an irregular heart beat), - irinotecan, etoposide, vinorelbine, ifosfamide (medicines used to treat cancer), - medicines containing ergot alkaloid derivatives such as ergotamine and diergotamine (used for treating migraines), - warfarin, acenocoumarol (blood thinners; blood tests may be required), - rifampicin, clarithromycin, telithromycin (antibiotics used to treat infections), - phenytoin (a medicine used to treat seizures), - carbamazepine (used to treat depression and epilepsy), - midazolam, triazolam, phenobarbital (medicines used to produce calmness or help you sleep), - St. John's Wort (an herbal preparation used to treat depression), - protease inhibitors (used to treat HIV infections), - ketoconazole except shampoo (used to treat Cushing's syndrome - when the body produces an excess of cortisol), - itraconazole, voriconazole, posaconazole (antifungals), - nefazodone (used to treat depression), - corticosteroids (such as dexamethasone and methylprednisolone), - anti-anxiety medicines (such as alprazolam), - tolbutamide (a medicine used to treat diabetes)
Croatian: Treba koristiti zamjenske ili dodatne nehormonske metode kontracepcije za vrijeme i do 2 mjeseca nakon primjene lijeka EMEND, - ciklosporin, takrolimus, sirolimus, everolimus (imunosupresivi), - alfentanil, fentanil (za liječenje boli), - kinidin (za liječenje nepravilnih otkucaja srca), - irinotekan, etopozid, vinorelbin, ifosfamid (lijekovi za liječenje raka), - lijekove koji sadrže derivate ergot alkaloida poput ergotamina i diergotamina (za liječenje migrene) - varfarin, acenokumarol (razrijeđivači krvi; možda će biti potrebne krvne pretrage) - rifampicin, klaritromicin, telitromicin (antibiotici za liječenje infekcija), - fenitoin (lijek za liječenje epileptičkih napadaja), - karbamazepin (za liječenje depresije i epilepsije), - midazolam, triazolam, fenobarbital (lijekovi za smirenje ili spavanje), - gospinu travu (biljni lijek za liječenje depresije), - inhibitore proteaze (za liječenje HIV infekcije), - ketokonazol, izuzev šampona (primjenjuje se za liječenje Cushingovog sindroma - kad se u tijelu stvara previše kortizola), - itrakonazol, vorikonazol, posakonazol (za liječenje gljivičnih infekcija), - nefazodon (za liječenje depresije), - kortikosteroide (poput deksametazona i metilprednizolona), - lijekove protiv tjeskobe (poput alprazolama), - tolbutamid (lijek za liječenje šećerne bolesti).
English: EMEND 40 mg hard capsules Aprepitant
Croatian: EMEND 40 mg tvrde kapsule aprepitant
English: Each hard capsule contains 125 mg of aprepitant.
Croatian: Jedna tvrda kapsula sadrži 125 mg aprepitanta.
English: Uncommon: may affect up to 1 in 100 people - feeling dizzy or sleepy - acne, rash - feeling anxious - burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind - pain or burning when urinating - feeling weak, generally feeling unwell - hot flushes/reddening of the face or skin - fast or irregular heart beat - fever with increased risk of infection, low number of red blood cells (shown in tests).
Croatian: Manje često: mogu se javiti u do 1 na 100 osoba - osjećaj omaglice ili pospanosti - akne, osip - osjećaj tjeskobe - podrigivanje, mučnina, povraćanje, žgaravica, bol u trbuhu, suha usta, vjetrovi - bol ili žarenje kod mokrenja - osjećaj slabosti, opće loše osjećanje - navale vrućine/crvenilo lica ili kože - ubrzani ili nepravilni otkucaji srca - vrućica s povećanim rizikom od infekcije, nizak broj crvenih krvnih stanica (pokaže se na krvnim pretragama).
English: EMEND 125 mg powder for oral suspension
Croatian: EMEND 125 mg prašak za oralnu suspenziju
English: C]-fosaprepitant, a prodrug for aprepitant, to healthy subjects, 57 % of the radioactivity was recovered in urine and 45 % in faeces.
Croatian: Nakon jednokratne intravenske primjene C]-fosaprepitanta, prolijeka aprepitanta, u dozi od 100 mg u zdravih ispitanika, 57% radioaktivnosti pronađeno je u mokraći, a 45% u fecesu.
English: What EMEND looks like and contents of the pack The 125 mg hard capsule is opaque with a white body and pink cap with “462” and “125 mg” printed radially in black ink on the body.
Croatian: EMEND 125 mg tvrda kapsula je neprozirna, s bijelim tijelom i ružičastom kapicom te poprečno otisnutim crnim oznakama "462" i "125 mg" na tijelu kapsule.
English: Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious or life-threatening reactions.
Croatian: Inhibicija CYP3A4 aprepitantom može povisiti koncentracije tih djelatnih tvari u plazmi, što može prouzročiti ozbiljne ili životno ugrožavajuće reakcije.
English: Each sachet contains 125 mg of aprepitant.
Croatian: Jedna vrećica sadrži 125 mg aprepitanta.
English: It is important to tell the doctor if you or the child are breast-feeding or are planning to breast-feed before taking this medicine.
Croatian: Važno je da prije uzimanja ovog lijeka obavijestite liječnika ako Vi ili dijete dojite ili namjeravate dojiti.
English: The following adverse reactions were observed in PONV studies in adults treated with aprepitant at a greater incidence than with ondansetron or in postmarketing use:
Croatian: Sljedeće nuspojave zabilježene su u ispitivanjima PONV-a, i u razdoblju nakon stavljanja lijeka u promet u odraslih koji su primali aprepitant i to češće nego u onih koji su primali ondanzetron:
English: Uncommon side effects (may affect up to 1 in 100 people) are: - dizziness, sleepiness, - acne, rash, - anxiousness, - burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind, - increased painful or burning urination, - weakness, generally feeling unwell, - hot flush, - fast or irregular heartbeats, - fever with increased risk of infection, lowering of red blood cells.
Croatian: Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba) su: - omaglica, pospanost, - akne, svrbež, - tjeskoba - podrigivanje, mučnina, povraćanje, žgaravica, bol u trbuhu, suha usta, vjetrovi - učestalo bolno mokrenje ili mokrenje uz osjećaj pečenja, - slabost, opće loše osjećanje - navale vrućine, - ubrzani ili nepravilni otkucaji srca - vrućica s povećanim rizikom od infekcije, smanjenje broja crvenih krvnih stanica
English: Uncommon side effects (may affect up to 1 in 100 people) are: - dizziness, sleepiness, - acne, rash, - anxiousness, - burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind, - increased painful or burning urination, - weakness, generally feeling unwell, - hot flush/reddening of the face or skin, - fast or irregular heartbeats, - fever with increased risk of infection, lowering of red blood cells.
Croatian: Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba) su: - omaglica, pospanost - akne, svrbež, - tjeskoba, - podrigivanje, mučnina, povraćanje, žgaravica, bol u trbuhu, suha usta, vjetrovi, - učestalo bolno mokrenje ili mokrenje uz osjećaj pečenja, - slabost, opće loše osjećanje, - navale vrućine/crvenilo lica ili kože, - ubrzani ili nepravilni otkucaji srca, - vrućica s povećanim rizikom od infekcije, smanjenje broja crvenih krvnih stanica.
English: C]-fosaprepitant, a prodrug for aprepitant to healthy subjects, 57 % of the radioactivity was recovered in urine and 45 % in faeces.
Croatian: Nakon jednokratne intravenske primjene C]-fosaprepitanta u dozi od 100 mg u zdravih ispitanika, 57% radioaktivnosti pronađeno je u mokraći, a 45% u fecesu.